Jul 2026· Frontiers in Drug Discovery· Vol 6· 0 citations· 108 references
TL;DR
A methodological framework for resistance-aware antimicrobial peptide discovery is proposed built upon three complementary principles: explainable and uncertainty-aware prediction, biologically constrained and rule-guided generative design, and iterative design–test–learn workflows capable of continuously incorporating new evidence.
Abstract
Therapeutic peptides have emerged as promising candidates for combating antimicrobial resistance, particularly against multidrug-resistant pathogens for which conventional antibiotics are becoming increasingly ineffective. Although artificial intelligence has accelerated antimicrobial peptide discovery through predictive modelling, generative design, and large-scale
in silico
screening, many current workflows remain fragmented, weakly interpretable, and only loosely connected to experimental feedback. In this Perspective, we propose a methodological framework for resistance-aware antimicrobial peptide discovery built upon three complementary principles: explainable and uncertainty-aware prediction, biologically constrained and rule-guided generative design, and iterative design–test–learn workflows capable of continuously incorporating new evidence. By organising existing methodologies into adaptive and transparent discovery systems, the proposed framework supports candidate prioritisation, optimisation, and iterative refinement under evolving resistance pressures. To demonstrate these concepts in practice, we present a workflow integrating interpretable prediction, uncertainty-aware prioritisation, rule extraction, and adaptive model updating. Collectively, these elements provide a roadmap for advancing antimicrobial peptide discovery from isolated predictive tasks toward integrated and evidence-driven discovery ecosystems.
A snapshot of AI-driven technologies for AMP design is provided and two modes of AI-driven technologies for AMP design are surveyed, one concentrated on identifying whether current data possess antimicrobial activity and the other on generating AMP candidates with potential therapeutic properties (generation-oriented).
Yong-Qiang Liu, Jie Hu, Ning Zhang et al.· Synthetic and Systems Biotec...· 0 citations
This review highlights how artificial intelligence bridges bacterial genomics and antimicrobial drug discovery and offers a strategic framework for the fast-tracked, cost-effective prioritization of therapeutic targets, making it a vital resource for tackling emerging pathogens.
Thayssa de Oliveira Teixeira, Ruana Carolina Cabral da Silva, M. Alves et al.· Journal of Computer-Aided Mo...· 1 citation
This study provides an experimental assessment of model-guided AMP discovery and a reproducible route from computational prediction to validated antimicrobial candidates, while revealing biases and generalizability limits of AI-based AMP inference.
S. Ojeda, P. Ávila, S. Castellanos et al.· bioRxiv· 0 citations
How recent advances in machine learning are reshaping AMP research is examined, driving a shift from large-scale discovery toward precision-guided prediction and design and emphasizing integrated generative-predictive pipelines, interpretable models, and closed-loop experimental validation as key enablers for the devel...
Artificial intelligence has moved convincingly beyond proof-of-concept in AMR diagnostics and discovery, but its path to the clinic now depends less on further algorithmic refinement than on prospective validation, equitable data representation, and interpretability standards that clinicians can reasonably trust.
AI has considerable potential to support AMR prediction and antimicrobial stewardship, but broader implementation will require rigorous validation, integration into clinical workflows, continuous monitoring and demonstration of clinical benefit.
Oana Frandeș, L. Azamfirei, Oana-Elena Branea et al.· Medicina· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.